Welcome to our dedicated page for YS Biopharma Co., Ltd. Ordinary Shares news (Ticker: YS), a resource for investors and traders seeking the latest updates and insights on YS Biopharma Co., Ltd. Ordinary Shares stock.
YS Biopharma (YS) delivers innovative vaccines and biologics through its proprietary PIKA immunomodulating technology. This news hub provides investors and healthcare professionals with timely updates on clinical developments, regulatory milestones, and strategic initiatives shaping the company's global biopharmaceutical operations.
Access consolidated information on YS's research progress, including rabies vaccine trials, hepatitis B therapeutics, and manufacturing expansions. Our repository ensures you stay informed about critical updates without searching multiple sources.
Key content includes earnings reports, partnership announcements, trial result publications, and regulatory submissions. All materials maintain factual accuracy focus, adhering to financial disclosure standards.
Bookmark this page for streamlined tracking of YS Biopharma's advancements in next-generation vaccine development and international market strategies.
LakeShore Biopharma (Nasdaq: LSB) has initiated a Biologics License Application to Pakistan's Drug Regulatory Authority for its PIKA rabies vaccine. The application is supported by successful pivotal trial results showing the vaccine's ability to provide accelerated protection in a one-week regimen, compared to conventional three- or four-week regimens. The Phase 3 trial involved 4,500 participants from the Philippines and Pakistan, demonstrating superior immunogenicity and safety. Pakistan, among the top five countries for human rabies cases, reports over 1.5 million dog bites and 2,000-5,000 human deaths annually. The vaccine, which received FDA orphan drug designation, utilizes proprietary PIKA adjuvant technology to produce stronger immune responses.
YS Biopharma announced a name change to LakeShore Biopharma, effective May 24, 2024. This rebranding aims to align with the company's global market positioning. The ticker symbol on Nasdaq will change from 'YS' to 'LSB' starting May 28, 2024. Shareholders' rights and the company's financial position remain unaffected. The CUSIP number will also stay the same.
YS Biopharma has announced the results of its Extraordinary General Meeting (EGM) held on May 21, 2024, in Hong Kong. Key resolutions passed include renaming the company to LakeShore Biopharma and appointing new directors Dave Chenn, Chunyang Shao, Zengjun Xu, Thomas Xue, and Adam Zhao. Additionally, the 2024 Share Incentive Plan was approved, and previous resolutions from the February 22, 2024 meeting were reaffirmed. The company is updating its records with the Cayman Islands Registrar and working with Nasdaq to update its trading symbols.
YS Biopharma, a global biopharmaceutical company, will hold an Extraordinary General Meeting on May 21, 2024, to change its name to LakeShore Biopharma and appoint new directors. Mr. Dave Chenn has been appointed as the Interim CEO with vast experience in technology, finance, and healthcare sectors.
YS Biopharma has received an additional 180-day extension from Nasdaq to regain compliance with the minimum bid price rule. The company did not meet the $1.00 bid price requirement and now has until October 21, 2024, to demonstrate compliance. Failure to do so may result in delisting.
FAQ
What is the current stock price of YS Biopharma Co., Ltd. Ordinary Shares (YS)?
What is the market cap of YS Biopharma Co., Ltd. Ordinary Shares (YS)?
